Pregnancy RSV Vaccine Update. Expert Guest: Professor Paul Heath. Join us for an update on the respiratory syncytial virus (RSV) vaccine given during pregnancy. Hear what the latest evidence is. This vaccine protects babies against a common cause of bronchiolitis which can be severe in newborns. The UK has made a decision to prevent against RSV with Abrysvo™, the maternal vaccine, manufactured by Pfizer. Previously the UK had been considering the use of Nirsevimab instead. This is an RSV monoclonal antibody for newborns (Beyfortus™, manufactured by Sanofi Pasteur). Both the vaccine and the antibody were recommended as safe and effective options in 2023 by the JCVI. After a cost-effectiveness analysis and financial tender by the Department of Health, a decision was made to move to Abrysvo™. The maternal vaccine success was revealed following a study involving over 7000 pregnant women, published in early 2023, the MATISSE trial. They showed that the Abrysvo™ maternal vaccine is highly effective at preventing severe infection in babies up to 180 days after birth. Vaccination is approved from 28 weeks of pregnancy in the UK.At the same time, the MELODY and HARMONIE trials showed the monoclonal antibody for babies Beyfortus™, currently unavailable in the UK, also effectively prevents RSV for up to 6 months after administration. This vaccine can be given to all babies anytime from birth.  We now we hear about what the evidence is now that the UK has been giving the vaccine since September 2024. Tune in now.